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Abstract
Background
Throughout the Ebola virus disease (EVD) epidemic in West Africa, field laboratory testing
for EVD has relied on complex, multi-step real-time reverse transcription PCR (RT-PCR)
assays; an accurate sample-to-answer RT-PCR test would reduce time to results and
potentially increase access to testing. We evaluated the performance of the Cepheid Gen-
eXpert Ebola assay on clinical venipuncture whole blood (WB) and buccal swab (BS) speci-
mens submitted to a field biocontainment laboratory in Sierra Leone for routine EVD testing
by RT-PCR (“Trombley assay”).
Methods and Findings
This study was conducted in the Public Health England EVD diagnostic laboratory in Port
Loko, Sierra Leone, using residual diagnostic specimens remaining after clinical testing.
EDTA-WB specimens (n = 218) were collected from suspected or confirmed EVD patients
between April 1 and July 20, 2015. BS specimens (n = 71) were collected as part of a
national postmortem screening program between March 7 and July 20, 2015. EDTA-WB
and BS specimens were tested with Xpert (targets: glycoprotein [GP] and nucleoprotein
[NP] genes) and Trombley (target: NP gene) assays in parallel. All WB specimens were
fresh; 84/218 were tested in duplicate on Xpert to compare WB sampling methods (pipette
versus swab); 43/71 BS specimens had been previously frozen.
In all, 7/218 (3.2%) WB and 7/71 (9.9%) BS samples had Xpert results that were reported
as “invalid” or “error” and were excluded, leaving 211 WB and 64 BS samples with valid
Trombley and Xpert results. For WB, 22/22 Trombley-positive samples were Xpert-positive
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(sensitivity 100%, 95% CI 84.6%–100%), and 181/189 Trombley-negative samples were
Xpert-negative (specificity 95.8%, 95% confidence interval (CI) 91.8%–98.2%). Seven of
the eight Trombley-negative, Xpert-positive (Xpert cycle threshold [Ct] range 37.7–43.4)
WB samples were confirmed to be follow-up submissions from previously Trombley-positive
EVD patients, suggesting a revised Xpert specificity of 99.5% (95% CI 97.0%–100%). For
Xpert-positive WB samples (n = 22), Xpert NP Ct values were consistently lower than GP Ct
values (mean difference −4.06, 95% limits of agreement −6.09, −2.03); Trombley (NP) Ct
values closely matched Xpert NP Ct values (mean difference −0.04, 95% limits of agree-
ment −2.93, 2.84). Xpert results (positive/negative) for WB sampled by pipette versus swab
were concordant for 78/79 (98.7%) WB samples, with comparable Ct values for positive
results. For BS specimens, 20/20 Trombley-positive samples were Xpert-positive (sensitiv-
ity 100%, 95% CI 83.2%–100%), and 44/44 Trombley-negative samples were Xpert-nega-
tive (specificity 100%, 95% CI 92.0%–100%). This study was limited to testing residual
diagnostic samples, some of which had been frozen before use; it was not possible to test
the performance of the Xpert Ebola assay at point of care.
Conclusions
The Xpert Ebola assay had excellent performance compared to an established RT-PCR
benchmark onWB and BS samples in a field laboratory setting. Future studies should eval-
uate feasibility and performance outside of a biocontainment laboratory setting to facilitate
expanded access to testing.
Introduction
The prolonged and devastating outbreak of Ebola virus disease (EVD) inWest Africa has
exposed a need for improved diagnostic methods to reduce result turnaround times and increase
access to testing without sacrificing test accuracy. To date, diagnosis of EVD has relied primarily
on real-time reverse transcription PCR (RT-PCR) performed in field biocontainment laborato-
ries on submitted venous whole blood (WB) or buccal swab (BS) specimens. Conventional
RT-PCR-based testing is cumbersome, requiring multiple processing steps from sample lysis
through nucleic acid extraction to the RT-PCR step itself. The use of blood samples has created
both logistical complications and biosafety concerns due to requirements for (a) collection and
transport of venipuncture blood (often collected with inadequate precautions due to resource
limitations, and then transported over substantial distances) and (b) multi-step processing of
this blood by skilled operators in a laboratory with adequate biocontainment capacity. Buccal
swabs have been used occasionally as diagnostic samples during the outbreak and are being
used extensively as part of the ongoing surveillance effort, particularly for postmortem screen-
ing. A highly accurate and fully automated RT-PCR assay capable of testing both blood and BS
specimens could greatly improve diagnostic capacity in countries affected by the outbreak.
The Cepheid GeneXpert Ebola assay received US Food and Drug Administration emer-
gency use authorization in March 2015 and WHO approval for emergency procurement in
May 2015; CE in vitro diagnostic compliance status was confirmed August 10, 2015. The Gen-
eXpert platform is an automated “sample-to-answer” system, integrating sample preparation,
virus inactivation, nucleic acid amplification, and detection; once inactivated sample is added
to a proprietary cartridge and loaded onto the platform, no further operator action is
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necessary to generate the result. The system has already demonstrated feasibility for use in
resource-limited settings for diagnosis of tuberculosis (e.g., [1]) and, accordingly, has been
widely deployed. The Xpert Ebola assay is a two-target RT-PCR assay separately detecting the
glycoprotein (GP) and nucleoprotein (NP) genes of the Ebola virus (EBOV). The Ebola assay
also includes two internal controls: an exogenous sample processing control (SPC) to deter-
mine whether amplification is inhibited during testing, and a sample adequacy control (SAC)
that detects an endogenous human genomic DNA target (human hydroxymethylbilane
synthase gene) [2] to confirm that sufficient host cellular material is present and intact in the
sample. Xpert Ebola assay components (buffers and cartridges) are optimally refrigerated
(although temperatures up to 28°C are tolerated), and the GeneXpert platform requires an
uninterrupted electricity supply. In this study, we sought to evaluate the field performance of
the Xpert Ebola assay on WB and BS samples submitted to an established field biocontain-
ment laboratory in Sierra Leone for routine clinical testing by a well-established RT-PCR
benchmark (Trombley assay) [3,4].
Methods
Ethics Statement
The study protocol was approved by the Sierra Leone Ethics and Scientific Review Committee,
the Sierra Leone Pharmacy Board, and the Partners Human Research Committee (Boston,
MA, US). Testing of excess specimens submitted for routine clinical testing was approved with
a waiver of informed consent.
Study Design and Setting
We conducted this study in the Public Health England (PHE) EVD diagnostic laboratory in
Port Loko, Sierra Leone (henceforth referred to as the field laboratory [FL]). Fresh EDTA-WB
venipuncture specimens (n = 218) submitted for routine clinical EVD diagnostic testing
between April 1 and July 20, 2015, first underwent clinical testing with the laboratory’s stan-
dard RT-PCR procedure (Trombley assay) and then were evaluated using the Xpert Ebola
assay on the GeneXpert platform. Given the automated sample-to-answer design of the Xpert
Ebola assay, it was not considered necessary to blind operators performing the Xpert assay to
the results of the Trombley assay. Fresh BS specimens (n = 28) submitted for clinical RT-PCR
testing (Trombley assay) between April 5 and July 20, 2015, as well as a selected set of frozen
BS specimens (n = 43, collected between March 7 and May 1, 2015) were also evaluated by the
Xpert Ebola assay; for previously frozen swabs, the Trombley assay was repeated in parallel
with Xpert testing. Initial plans for sample testing were to test all WB and BS samples consecu-
tively submitted to the laboratory. However, because of decreasing case rates over the course of
the study, we ultimately selected some samples for testing by Xpert based on prior Trombley
results (positive/negative). In sum, approximately 50 laboratory staff members participated in
testing using the Trombley assay, Xpert assay, or both. All staff were trained utilizing a formal
training procedure before operating instruments and interpreting tests.
Clinical RT-PCR Testing Procedures (Trombley Assay)
On receipt in the FL, EDTA-WB samples and BS samples collected and transported in Sigma-
Virocult tubes (Medical Wire and Equipment) were transferred to a flexible film isolator (FFI)
for lysis and inactivation. For blood samples, viral RNA was typically manually extracted from
50 μl of plasma using the QIAamp Viral RNA Kit (Qiagen); sample extraction volumes were
adjusted from those recommended by Qiagen to minimize inhibition observed when larger
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volumes of field samples were used. For ~15% of blood samples, 80 μl of plasma was extracted
using the EZ1 Virus Mini Kit v2.0 (Qiagen) in conjunction with the EZ1 platform (Qiagen).
For fresh and frozen BS specimens, the swab was agitated in the viral transport medium,
and the medium then harvested and centrifuged at 3,000 rpm (665g) for 1–2 min. RNA was
extracted from 25 μl of clarified supernatant using the EZ1 Virus Mini Kit v2.0 (Qiagen) in
conjunction with the EZ1 platform (Qiagen); for four fresh BS samples, RNA was extracted
manually using the QIAamp Viral RNA Kit (Qiagen).
Intact MS2 phage was included in all RNA extractions as an exogenous internal control.
Extracts were resuspended in 60 μl of AVE buffer (Qiagen), and qualitative RT-PCR for detec-
tion of EBOV was performed using the Trombley assay [3,4]. Samples were usually tested on
the day of receipt in the laboratory; samples received in the evening were tested the next morn-
ing (maximum delay of 12 h). Details of Trombley assay performance have been described
recently [4]. Duplex RT-PCR was performed with primers/probes directed against the EBOV
NP gene (FAM channel) and the MS2 genome (Alx532 channel; in-house assay) using TaqMan
Fast Virus 1-Step Master Mix (Applied Biosystems) on a SmartCycler II platform (Cepheid).
Assays were conducted with the following cycling conditions: 50°C for 5 min (one cycle); 95°C
for 20 s (one cycle); 95°C for 3 s and 60°C for 30 s (45 cycles). A single fluorescence read was
taken at the end of each 60°C step. Samples with cycle threshold (Ct) 40 and a positive inter-
nal control were interpreted as EBOV negative; if the internal control failed, the result was
interpreted as a sample failure, and the test was repeated. Samples with Ct> 0 and< 40 with
or without a positive internal control were interpreted as EBOV positive.
Xpert Ebola Assay Testing Procedures
The GeneXpert Ebola assay was performed using the GeneXpert Ebola Assay kit (REBOLA-50;
Cepheid), as per the manufacturer’s instructions (RUO package insert 301–4732, Revision 1,
March 2015). All steps prior to loading test cartridges onto the Xpert instrument platform were
carried out in FFIs. EDTA-WB was prepared either by pipetting 100 μl of blood into 2.5 ml of
sample reagent buffer or by allowing EDTA-WB to wick up one of the swabs provided with the
Xpert Ebola test kits until the swab was fully wetted, then transferring the swab to 2.5 ml of
sample reagent buffer (both sampling methods are recommended by the manufacturer). Fresh
BS specimens were agitated in their Sigma-Virocult tube, and 100 μl of crude swab medium
was then transferred to 2.5 ml of sample reagent buffer. Fresh excess clinical samples were usu-
ally tested by Xpert within 1–2 d of testing by Trombley assay, but storage of either the fresh
clinical sample or the sample in Xpert sample reagent buffer at 4°C for up to 6 d prior to testing
on Xpert was permitted. Archived BS samples, stored at −80°C as crude BS medium, were
thawed (either for 30 min at room temperature or for 24 h at 4°C), then gently agitated before
transferring 100 μl of medium to 2.5 ml of sample buffer.
All samples were incubated in sample reagent for 20 min at room temperature, then trans-
ferred to Xpert Ebola test cartridges, taking care not to introduce air bubbles. Cartridges were
loaded onto a GeneXpert XVI platform (Cepheid), operated according to the manufacturer’s
instructions. The following results were interpreted as Ebola positive: Ebola GP detected and
Ebola NP detected; Ebola GP detected and Ebola NP not detected; Ebola GP not detected and
Ebola NP detected. Results were interpreted as Ebola negative if neither Ebola GP nor Ebola
NP was detected, providing the SPC and SAC controls passed. Negative tests in which the SPC
or SAC failed or fell outside a cutoff Ct value preset by the manufacturer were reported by the
system software as “invalid.” Tests were reported by the system as “error” if the probe check
control failed or process errors occurred (e.g., “motion of syringe drive not detected”). Tests in
which inadequate data were collected by the system (e.g., the test run was interrupted due to
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sample loading error or power loss during the test run) were reported by the system software as
“no result.”When possible, tests reported as invalid/error/no result were repeated using newly
extracted sample. If a valid result was obtained on repeat testing, the valid result was used for
analysis.
Data Management and Statistical Analysis
Data entry was independently performed by at least two different members of the study team,
and the data entered were then reconciled. Sensitivity was defined for each specimen type as
the proportion of Trombley RT-PCR-positive samples that tested positive by the Xpert Ebola
assay, and specificity was defined for each specimen type as the proportion of Trombley
RT-PCR-negative samples that tested negative by the Xpert Ebola assay. Samples that gener-
ated a final report of invalid/error/no result from the Xpert Ebola assay were excluded from
sensitivity and specificity calculations. 95% CIs for proportions were calculated using the exact
binomial (Clopper—Pearson) formula. Method agreement was assessed by Bland—Altman
analysis [5] using Stata 13 (StataCorp).
This study has been reported according to STARD guidelines (S1 Table).
Results
Testing of Residual Clinical EDTA—Whole Blood Specimens
Patient gender was recorded for 186/218 WB specimens, of which 109 (58.6%) were from male
and 77 (41.4%) from female patients. Patient age was recorded for 192 specimens, and ranged
from 11 mo to 105 y (mean 33.2 y, standard deviation [SD] 17.4; median 32, interquartile
range [IQR] 22–41). In all, 94 (43.3%) of the WB specimens were tested by Xpert and Trombley
assays on the same day. The remaining specimens were tested by the Xpert assay 1–6 d follow-
ing Trombley testing (mean 1.8 d, SD 1.1; median 1, IQR 1–2). Ambient temperatures in the
FL during testing procedures ranged from 23.0 to 31.7°C (mean 27.9), and ambient humidity
ranged from 45% to 87% (mean 64.9%).
Nine of 218 WB specimens initially generated an Xpert report of “invalid,” “error,” or “no
result.” Four such results were due to internal control failures (two SPC failures, one SAC fail-
ure, and one sample with both SPC and SAC failures; all reported as “invalid”), three were due
to probe check or process errors (reported as “error”), and two were due to automated loading
errors during the assay run (reported as “no result”) (detailed results are provided in S2 Table).
Adequate volume was available for repeat testing of two of these specimens (the two associated
with loading errors on initial testing), both of which generated valid results that were included
in subsequent analyses per the study protocol. The seven specimens with insufficient volume
for repeat testing had all tested negative by the Trombley assay (S2 Table).
In all, 211 WB specimens generated valid Xpert and Trombley results. Of these, 22/22 speci-
mens that tested positive by the Trombley assay were positive by Xpert (sensitivity 100% [95%
CI 84.6%–100%]) (Table 1), and 181/189 specimens that tested negative by the Trombley assay
were negative by Xpert (specificity 95.8% [95% CI 91.8%–98.2%]), with the remaining 8/189
Trombley-negative specimens generating positive Xpert results (Table 1).
Ct values for WB specimens that tested positive by Trombley assay (NP gene target) ranged
from 17.4 to 39.8 (mean 26.7, SD 7.2; median 24.0, IQR 19.4–34.7) (Table 2). Ct values for
Xpert-positiveWB specimens ranged from 16.9 to 43.4 (mean 29.8, SD 8.5; median 30.3, IQR
21.7–37.5) for the NP gene target and from 22.0 to 42.7 (mean 31.8, SD 7.2; median 29.5, IQR
24.9–39.0) for the GP gene target (Table 2). When comparing the results of both tests for concor-
dant specimens, Ct values obtained for the NP gene target by Trombley and Xpert testing did
not vary systematically (mean difference −0.04, 95% limits of agreement −2.93, 2.84; Fig 1A). For
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Xpert tests, Ct values obtained for the NP gene target were systematically lower than correspond-
ing GP target Ct values (mean difference −4.06, 95% limits of agreement −6.09, −2.03; Fig 1B).
For specimens yielding valid Xpert results, SPC Ct values ranged from 31.4 to 37.4 (mean 32.9,
SD 2.5; median 32.7, IQR 32.4–33.3) and SAC Ct values ranged from 23.7 to 35.1 (mean 30.0, SD
1.6; median 30.3, IQR 29.4–30.9).
Further examination of the eight discordant specimens (Trombley-negative/Xpert-positive;
Table 2) revealed that seven of these specimens were collected from known EVD patients (i.e.,
patients who had tested positive by the Trombley assay on prior testing) who were receiving
follow-up testing to monitor for clearance of viremia. The Ct values obtained by Xpert testing
for these seven discordant specimens were high (37.7–43.4 for the NP target, n = 6; 40.6–41.7
for the GP target, n = 2; Table 2), suggesting low-level viremia in the context of viral clearance.
After resolving these seven discordant results in favor of Xpert, 181/182 true negatives were
Xpert-negative (revised specificity of 99.5%, 95% CI 97.0%–100%; Table 1).
For Xpert testing, all 218 WB specimens were sampled by using a precision pipettor to add a
100 μl aliquot of EDTA-WB directly into the sample reagent; 84 of the specimens were also
sampled by wicking EDTA-WB onto a swab and placing the swab into the sample reagent (see
Methods). Five specimens generated invalid Xpert results in either the pipette- or swab-sam-
pled test. Overall, 78/79 (98.7%) specimens with valid, paired pipette- and swab-sampled tests
had concordant positive or negative Xpert results. The single discordant pair of results was
from a Trombley-negative WB specimen that tested negative by Xpert for the pipette-sampled
test and positive (NP Ct = 39.7, GP Ct = 41.8) for the swab-sampled test. Further examination
of this specimen revealed that it was collected from a known EVD patient (i.e., previously
Trombley-positive) who was being monitored for viral clearance. Ct values for positive speci-
mens were well matched between the two sampling methods for both the NP (mean difference
0.45, SD 0.82) and GP (mean difference 0.10, SD 0.57) gene targets.
Testing of Residual Clinical Buccal Swab Specimens
BS samples (n = 71) used for the study were submitted as part of the national postmortem sur-
veillance program. Patient gender was recorded for 64 specimens, of which 28 (43.8%) were
from female and 36 (56.3%) were from male patients. Patient age was recorded for 64 speci-
mens, and ranged from 1 d to 96 y (mean 25.9 y, SD 28.6; median 10, IQR 1–50). Of the 71 BS
specimens, 28 were fresh at the time of testing, and 43 were frozen and thawed. Of the fresh
specimens, 17 (60.7%) were tested by Xpert and Trombley assays on the same day. The remain-
ing fresh specimens were tested by the Xpert assay 1–2 d following Trombley testing (mean
1.64 d, SD 0.48; median 1, IQR 1–2). Frozen BS specimens were tested by Xpert and Trombley
assays in parallel. Ambient temperatures in the FL during testing procedures ranged from 23.3
to 26.1°C (mean 26.3), and ambient humidity ranged from 60% to 69% (mean 64.9%).
Table 1. Sensitivity and specificity of the Xpert Ebola assay versus the Trombley assay performed on clinical whole blood and buccal swab
samples.
Sample Type Sensitivity (Percent; 95% CI) Speciﬁcity (Percent; 95% CI) Adjusted Speciﬁcity* (Percent; 95% CI)
WB (n = 211) 22/22 (100%; 84.6%–100%) 181/189 (95.8%; 91.8%–98.2%) 181/182 (99.5%; 97.0%–100%)
BS (n = 64) 20/20 (100%; 83.2%–100%) 44/44 (100%; 92.0%–100%) N/A
*Adjusted speciﬁcity is based on the resolution of seven discordant Trombley-negative/Xpert-positive tests in favor of Xpert based on prior Trombley-
positive test results for those individuals.
N/A, not applicable.
doi:10.1371/journal.pmed.1001980.t001
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Table 2. Comparison of cycle threshold values for whole blood and buccal swab specimens that tested positive by Trombley and/or Xpert assay.
Specimen Type Trombley/Xpert Test Agreement Trombley NP Target Xpert
NP Target GP Target
WB Concordant 21.2 21.7 25.4
Concordant 37.1 35.1 38.7
Concordant 26.6 25.5 30.1
Concordant 22.8 23.8 26.2
Concordant 33.0 31.6 35.4
Concordant 17.4 18.5 24.1
Concordant 22.8 25.9 28.8
Concordant 37.4 35.6 42.2
Concordant 19.4 19.8 24.5
Concordant 34.6 34.4 38.5
Concordant 18.3 20.8 25.3
Concordant 23.6 24.3 28.2
Concordant 18.7 18.6 24.3
Concordant 24.0 21.8 24.8
Concordant 19.3 19.4 23.2
Concordant 18.2 16.9 22.0
Concordant 30.5 32.4 35.5
Concordant 39.8 39.4 42.7
Concordant 35.1 36.7 N/A
Concordant 23.9 22.1 26.6
Concordant 28.7 29.0 32.5
Concordant 34.9 35.0 39.1
Discordanta N/A 43.1 N/A
Discordanta N/A 41.8 N/A
Discordanta N/A N/A 41.7
Discordantb N/A N/A 42.1
Discordanta N/A 41.4 N/A
Discordanta N/A 37.7 40.6
Discordanta N/A 43.4 N/A
Discordanta N/A 38.6 N/A
BS Concordant 23.5 23.5 28.2
Concordant 25.5 24.2 29.3
Concordant 31.1 25.1 28.9
Concordant 28.0 27.7 31.4
Concordant 39.4 34.8 37.4
Concordant 28.9 25.1 30.3
Concordant 21.7 18.6 23.8
Concordant 35.4 33.7 37.3
Concordant 28.5 26.0 30.1
Concordant 27.3 23.6 27.8
Concordant 32.1 29.0 32.0
Concordant 27.5 25.0 29.5
Concordant 26.2 22.2 26.8
Concordant 29.1 22.4 26.8
Concordant 24.5 19.6 23.5
Concordant 28.1 26.3 30.2
(Continued)
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Eight of the frozen BS specimens initially generated invalid Xpert results, all of which were
due to SAC failure. SPC Ct values for these eight samples ranged from 32.0 to 33.5 (mean 32.5)
(S2 Table), which was comparable to the SPC Ct values for BS specimens that generated valid
Xpert results (range 31.2–36.0, mean 32.9). Adequate volume was available for repeat testing of
six of these specimens, one of which generated a valid result that was included in subsequent
analyses, and five of which again generated invalid results due to SAC failure (S2 Table).
Overall, 64 BS specimens (28 fresh and 36 frozen) generated valid Xpert and Trombley
results. All of the 20 specimens that tested positive by Trombley assay were positive by Xpert
(sensitivity 100%, 95% CI 83.2%–100%; Table 1), and all of the 44 specimens that tested negative
by Trombley assay were negative by Xpert (specificity 100%, 95% CI 92.0%–100%; Table 1).
Ct values for BS specimens that tested positive by Trombley assay (18/20 of which were fro-
zen specimens) ranged from 21.7 to 39.4 (mean 28.4, SD 4.0; median 28.1, IQR 25.7–30.3)
(Table 2). Ct values for Xpert-positive BS specimens ranged from 18.6 to 34.8 (mean 24.9, SD
4.1; median 24.6, IQR 22.4–26.7) for the NP gene target and from 23.5 to 37.4 (mean 29.0, SD
3.7; median 29.1, IQR 26.8–30.5) for the GP gene target (Table 2). In contrast to WB speci-
mens, Ct values for the NP gene target in BS specimens were consistently higher by Trombley
assay than by Xpert testing (mean difference 3.49, 95% limits of agreement −0.44, 7.41; Fig
1C). Ct values obtained by Xpert testing for the NP gene target were again systematically lower
than the corresponding Xpert GP Ct values (mean difference −4.11, 95% limits of agreement
−5.43, −2.79; Fig 1D).
For all samples with valid test results, SPC Ct values were similar between fresh and frozen
BS specimens, ranging from 31.2 to 35.0 (mean 32.6, SD 0.9; median 32.6, IQR 32.1–32.9) for
fresh specimens and from 31.6 to 36.0 (mean 33.1, SD 0.9; median 32.9, IQR 32.6–33.5) for fro-
zen specimens. In contrast, SAC Ct values tended to be higher in frozen than in fresh specimens,
ranging from 24.8 to 33.9 (mean 28.9, SD 2.4; median 28.9, IQR 26.9–30.8) for fresh specimens
and from 27.5 to 37.1 (mean 32.4, SD 2.8; median 32.7, IQR 29.7–35.0) for frozen specimens.
Discussion
In this field study, the Cepheid GeneXpert assay performed onWB demonstrated 100% sensitiv-
ity and 95.8%–99.5% specificity compared to the benchmark Trombley assay performed on
paired plasma samples. When the Xpert and Trombley assays were performed on BS samples,
either fresh or frozen, the Xpert assay had 100% sensitivity and 100% specificity compared to the
Trombley assay. The Trombley assay was used as the benchmark for this study because it was
Table 2. (Continued)
Specimen Type Trombley/Xpert Test Agreement Trombley NP Target Xpert
NP Target GP Target
Concordant 30.3 22.4 26.3
Concordant 30.3 26.8 30.5
Concordant 27.1 23.1 27.0
Concordant 23.6 19.2 23.5
Discordant test outcomes were Trombley-negative/Xpert-positive test results.
aSamples found to be from known EVD patients (i.e., patients who had tested positive by the Trombley assay on prior testing) who were receiving follow-
up testing to monitor for clearance of viremia.
bThe disease status of this patient is unknown.
N/A, not applicable (negative test result).
doi:10.1371/journal.pmed.1001980.t002
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the clinical testing method employed by the PHE field biocontainment laboratory during the
study period, and the assay has demonstrated excellent performance over the course of its
deployment [4]. In RT-PCR-positive blood samples, Trombley (NP target) Ct values closely
matched Xpert NP Ct values, despite the differences in samples tested (plasma versusWB). The
WB sampling method used (conventional pipettor versus swab, both recommended in the Xpert
Ebola package insert) did not appear to impact the results, and Ct values for samples collected
using the two methods were roughly equivalent, despite the lower precision expected when sam-
pling blood with a swab. Study operators found the swab sampling method to be straightforward
and perhaps preferable to use of a pipettor given that pipette tips were treated as sharps in the
laboratory and elimination of use of the pipettor reduced overall contamination risk.
Fig 1. Evaluation of cycle threshold value agreement. Bland—Altman plots to evaluate agreement between cycle threshold values generated for the NP
target by the Trombley versus Xpert assay for WB (A) and BS (C) samples and those generated by Xpert for the NP versus GP target for WB (B) and BS (D)
samples. The blue line in each plot represents the “bias,” or average difference between the two methods. The red lines represent the 95% limits of
agreement. The green line represents the line of no bias.
doi:10.1371/journal.pmed.1001980.g001
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Eight WB samples tested positive by the Xpert assay while their paired plasma samples were
negative by the Trombley assay, leading to an initial specificity estimate of 95.8%. Notably, 7/8
of these samples were confirmed to be from patients who earlier in their disease had tested pos-
itive by the Trombley assay and were thus being monitored for clearance of viremia. This
allowed the discordance to be resolved in favor of Xpert and raised the Xpert specificity esti-
mate to 99.5%. The Xpert Ct values for these eight discordant samples ranged from 37.7 to
43.4, all at the upper range of detection for the assay. The Trombley internal control performed
well in all eight discordant samples, indicating that inhibition of amplification was not a prob-
lem (of note, the Trombley internal control is an exogenous target [see Methods] that is spiked
into the sample prior to nucleic acid extraction and thus does not depend on sample integrity).
One potential explanation for the observed discordance is that the Xpert assay is more analyti-
cally sensitive than the Trombley assay; however, a direct comparison of the limit of detection
of the two assays is not available. Interestingly, a recent publication comparing the perfor-
mance of the BioFire FilmArray Ebola assays [6] to the US Centers for Disease Control and
Prevention EBOV quantitative RT-PCR (qRT-PCR) assay suggests an alternative explanation.
In that study, the authors identified clinical samples for which WB tested positive by both Fil-
mArray and qRT-PCR, but the corresponding plasma prepared from the same sample tested
negative on both assays. The authors interpreted these findings as “a trend toward the virus
clearing from plasma before clearing from whole blood,” and suggested that this was poten-
tially related to early infection of monocytes and was supported by precedents observed with
infections with other RNA viruses. Future research should evaluate the hypothesis that plasma
(as used in the Trombley assay) is potentially a less optimal sample type than WB for EVD test-
ing, particularly in late stages of disease.
The Xpert platform offers advantages over conventional RT-PCRmethods in its automated,
integrated sample-to-answer configuration; this ease of use has allowed broad deployment in a
variety of testing settings. However, the platform requirements are not trivial for deployment in
truly resource-limited settings, given requirements for a constant supply of electricity and
potentially for refrigeration of cartridges and other assay reagents. Moreover, despite the clear
value of peripheral deployment of such a platform (i.e., outside of a field biocontainment labora-
tory setting), an operator with some laboratory expertise will still be required for platform and
assay validation, quality control, and maintenance. Our experience indicated that troubleshoot-
ing by an experienced technician was required throughout the course of the study, including for
evaluation of invalid results, stuck modules, and unexpected equipment shutdowns requiring
platform reboot. It is difficult to imagine inexperienced operators coping with such issues with-
out significant technical support. During our study, the failure of tests or entire runs for reasons
unrelated to sample quality required repeat testing that in real practice would clearly impact
result turnaround times. Finally, if implementation outside of a controlled laboratory setting is
desired, the biosafety risks associated with loading cartridges outside containment must be care-
fully assessed. The Xpert Ebola assay is designed such that 20 min after a sample has been added
to sample reagent, it is to be considered inactivated, and thus could be loaded into the cartridge
outside of an FFI (“glove box”). The Xpert Ebola assay package insert (CE-IVD Xpert Ebola
assay package insert, Revision A, June 2015) states that the sample reagent (2.5 ml) has been
shown to completely inactivate 4.6 × 106 PFU of added live EBOV, and in a published study [2]
the reagent achieved at least a 6-log reduction of infectious EBOV. However, at the peak of
EVD, viral load in blood can exceed 108 RNA copies/ml [7]; given the challenge inherent in
comparing viral RNA copies/ml and PFU/ml [2], it is unclear whether a 6-log “knock-down”
may or may not still leave a small amount of viable virus in samples with very high viral load.
Accordingly, in our study we chose to do all sample manipulation (including loading of car-
tridges with lysed and denatured samples) inside an isolator. Our laboratory staff also would
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have preferred to wipe cartridges down with 5,000 ppm sodium hypochlorite prior to removing
them from the glove box and loading them on the Xpert platform, but the effects this might
have on cartridge function are not yet known. All of these considerations have implications for
operating the Xpert Ebola assay outside of a containment laboratory setting.
Our study had some limitations. First, sample processing methods were dictated by the use
of excess clinical specimens for the study. Our BS processing procedure deviated from that
intended in the package insert, in that we added aliquots of crude BS sample into the Xpert
inactivation buffer, rather than adding the swab itself directly to the inactivation buffer imme-
diately after collection. Additionally, we had to include a subset of frozen BS samples in our
study in order to have sufficient numbers of positive samples for analysis, because of dropping
EVD case rates over the course of the study. These samples contributed all of the invalid BS
results. However, we anticipate that use of the intended Xpert processing protocol and fresh
(rather than frozen) samples would further improve results over the excellent performance we
observed here. Specifically, we would expect that placing the entire BS (with all of its cellular
material, rather than just a fraction of it) directly into the inactivation buffer would increase
assay yield, and that use of exclusively fresh BS specimens would lower the overall rate of
invalid results. The thawing protocol used in this study may have contributed to the number of
invalid BS tests, as 7/8 invalid results were observed in a batch of BS specimens that were
thawed for 24 h at 4°C (possibly leading to increased degradation). However, suboptimal sam-
ple collection and handling prior to submission to the laboratory could also contribute to SAC
failure; thus, invalid test rates will need to be evaluated in a larger study of fresh BS specimens
submitted for routine testing.
The second limitation of this study was that we were ultimately unable to complete a
planned point-of-care (POC) sample collection sub-study due to unanticipated changes in
available clinical sites for our study. While sampling of WB with a swab in many ways simu-
lates capillary blood collection and while our results suggest that the swab method works well
in this assay, we cannot necessarily assume that capillary blood collected with a swab from a
fingerstick will perform equivalently to venous WB sampled with a swab. However, three field
studies thus far suggest that capillary blood does work well (in comparison to WB) for EVD
diagnosis [4,8,9]. Overall, given that residual clinical WB and BS samples submitted to a work-
ing EVD field diagnostic laboratory were used for this study, the study population fully repre-
sents the population of interest.
There is general consensus that a highly sensitive and specific, less invasive (e.g., fingerstick
or BS), cost-effective, POC diagnostic for EVD would be the ideal tool [10–12], but despite the
explosion of test development activity in parallel with the outbreak response, it has been diffi-
cult to develop one test capable of meeting all of these goals. At the time of writing, ten assays
have received US Food and Drug Administration emergency use authorization [13] and six
have received WHO emergency use assessment and listing [14]; published data for field perfor-
mance exist for only a few of these assays. The Corgenix lateral flow immunoassay for detection
of EBOV VP40 matrix protein performed very well for fingerstick testing in a recent field study
[4] and satisfies additional critical goals of low cost and POC use, but its sensitivity and speci-
ficity were lower than that of benchmark RT-PCR assays performed in parallel (including the
Trombley assay used in this study), leading to controversy around optimal deployment [15].
The BioFire FilmArray sample-to-answer molecular assays (BioFire FilmArray BioThreat
panel and FilmArray BT E-panel) have the advantage of requiring no refrigeration and per-
formed well in three recent studies [6,16,17] compared to the EBOV RT-PCR assays developed
by the US Centers for Disease Control and Prevention [6,16] or the Trombley assay used by
PHE [17]. However, the analytical sensitivity compared to the Xpert Ebola test was inferior [2].
The FilmArray platform is not designed for high-throughput testing, potentially limiting its
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deployment. The Cepheid Xpert Ebola assay has some advantages over these other diagnostics:
(a) higher throughput (multiple modules per platform) while maintaining a low-complexity
sample-to-answer format; (b) highly accurate performance, as evidenced in this study; and (c)
relatively rapid turnaround time (we estimate from our experience that time from sample
receipt to result would be ~2.5 h, versus ~4 h for the Trombley assay). However, it remains to
be seen whether the test can truly be deployed at POC (or near POC) and in what types of facil-
ities; moreover, whether the performance of the assay in fingerstick samples is equivalent to its
performance in WB should be formally evaluated, as should its performance with a larger set of
fresh BS samples. As noted above, additional questions remain regarding complete inactivation
of virus in samples with very high viral loads (and thus about optimal biosafety practices for
loading cartridges); requirements for refrigeration, uninterrupted electricity, and platform vali-
dation and maintenance must be considered; and, finally, test cost must be considered and
potentially negotiated to allow wide deployment in areas of maximal need. In sum, our data
indicate that the Xpert Ebola assay has excellent performance in a field laboratory setting using
both WB and BS specimens and thus provides the opportunity for highly accurate, rapid sam-
ple-to-answer diagnosis of EVD; future operational research should examine the spectrum of
clinical testing scenarios to determine which are feasible for Xpert Ebola assay deployment.
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Editors' Summary
Background
During the recent Ebola virus disease (EVD) outbreak in West Africa, there were more
than 28,000 confirmed, probable, and suspected cases of EVD and more than 11,000
deaths from EVD. Ebola virus is transmitted to people from wild animals and spreads in
human populations through contact with the bodily fluids (including blood, saliva, and
urine) or organs of infected people and through contact with bedding and other materials
contaminated with bodily fluids. The symptoms of EVD, which start 2–21 days after infec-
tion, include fever, headache, vomiting, diarrhea, and internal and external bleeding.
Infected individuals are not infectious until they develop symptoms, but they remain infec-
tious as long as their bodily fluids contain virus, which can be several weeks. There is no
proven treatment for EVD, but supportive care—given under strict isolation conditions to
prevent the spread of the disease—improves survival. Currently, there are no licensed
Ebola vaccines, but two candidate vaccines are being evaluated.
WhyWas This Study Done?
EVD diagnosis during the recent epidemic relied on multi-step reverse transcription poly-
merase chain reaction (RT-PCR) assays (for example, the Trombley assay) performed in
field biocontainment laboratories on blood obtained from a vein using a needle (venipunc-
ture) or on samples of cells and saliva collected from the mouth lining using a swab (buccal
swab); buccal swabs are mainly used for surveillance, particularly postmortem screening.
Prior to RT-PCR, the sample must be inactivated and nucleic acid extracted. An accurate,
fully automated “sample-to-answer” assay that is capable of testing both whole blood and
buccal swabs and that minimizes the potential exposure of laboratory personnel to the
Ebola virus could greatly improve EVD diagnosis. Here, the researchers evaluate the per-
formance of the Cepheid GeneXpert Ebola assay on whole blood samples and buccal swabs
sent to a field laboratory in Sierra Leone for routine testing using the Trombley assay. The
Xpert assay is an automated RT-PCR system that integrates all the steps needed to deter-
mine the presence of Ebola virus; once the test sample has been inactivated and added to a
proprietary cartridge, no further operator action is necessary to generate the result.
What Did the Researchers Do and Find?
The researchers tested 218 whole blood specimens collected from patients with suspected
or confirmed EVD using both the Trombley and the Xpert assay. After excluding a few
samples that gave Xpert results that were reported as “invalid” or “error,” 22 out of 22
Trombley-positive samples were Xpert-positive, and 181 out of 189 Trombley-negative
samples were Xpert-negative. That is, the Xpert assay had a sensitivity (true positive rate)
of 100% and a specificity (true negative rate) of 95.8% compared to the benchmark assay.
Notably, seven of the eight Trombley-negative but Xpert-positive blood samples were fol-
low-up samples obtained from previously Trombley-positive patients, which suggests that
the specificity of the Xpert test was actually 99.5%. When the Xpert assay was used to test
71 buccal swabs, the sensitivity and specificity of the Xpert assay were both 100%. Finally,
Xpert results obtained using a pipette versus a swab to pick up a portion of blood for test-
ing were concordant in 78 out of 79 samples; this test was done in part to get an indication
of whether the Xpert Ebola assay will work on fingerstick samples—blood samples
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obtained by using a sterile lancet to pierce the fingertip and then collecting the blood with
a swab; this collection method is more easily done in the field at point of care than
venipuncture.
What Do These Findings Mean?
These findings show that, compared to an established RT-PCR Ebola virus assay, the
Xpert Ebola assay performed well on both whole blood samples and buccal swabs in a field
laboratory setting. Although sampling of blood with a swab partly simulated the perfor-
mance of the Xpert assay on fingerstick samples collected at point of care, fingerstick sam-
ple collection will need to be tested directly before the Xpert assay can be used to test
individuals for Ebola virus by this method at point of care. Further studies are also needed
to evaluate the feasibility and performance of the Xpert assay in a range of clinical settings
to determine where and when this assay can be deployed; the need for an uninterrupted
power supply and, in some settings, for refrigeration of reagents may prevent its deploy-
ment in some resource-limited settings. Ultimately though, these findings suggest that the
use of the Xpert Ebola assay could facilitate expanded access to Ebola virus testing.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001980.
• TheWorld Health Organization (WHO) provides information about EVD, information
about potential EVD vaccines and therapies, and regular updates on the West African
EVD epidemic; the WHO website also provides information about efforts to control
Ebola in the field and personal stories from people who have survived EVD
• The UK National Health Service Choices website provides detailed information on EVD
• The US Centers for Disease Control and Prevention also provides information about
EVD
• More information on the Xpert Ebola test and authorization for its emergency use is
available from the US Food and Drug Administration and fromWHO
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